Real-World Evidence

Read More | No Comments

Regulatory Science Lab

Real-World Evidence

Research using real-world data and advanced methods to understand how health technologies perform in clinical practice.

2025

  1. Weymann D, Krebs E, Pollard S, McPhail M, Bosdet I, Yip S, Weppler AM, Karsan A, Anderson H, Bubela T, Law MR, Kesselheim A, Regier DA. Patient and population impacts of multi-gene panel and pembrolizumab coverage in metastatic melanoma. Journal of the National Cancer Institute. 2025; djaf307.
  2. Krebs E, Weymann D, Ho C, Weppler A, Bosdet I, Karsan A, Hanna TP, Pollard S, Regier DA. Clinical effectiveness and cost-effectiveness of multigene panel sequencing in advanced melanoma: A population-level real-world target trial emulation. JCO Precision Oncology. 2025; (9):e2400631:1–12.
  3. Krebs E, Weymann D, Lim H, Yip S, Regier DA. Determining the survival impact and cost-effectiveness of multi-gene panel sequencing in metastatic colorectal cancer with super learning approaches. Health Services Research. 2025; e70009. Advance online publication.

2024

  1. Krebs E, Weymann D, Ho C, Regier DA. Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small lung cancer: A population-based study. The Lancet Regional Health – Americas. 2024; (40):1–11.
  2. Pataky RE, Weymann D, Bosdet I, Yip S, Bryan S, Sadatsafavi M, Peacock S, Regier DA. Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer. Journal of Cancer Policy. 2024; (41):1–8.
  3. Regier DA, Loewen R, Chan B, Ehman M, Pollard S, Friedman JM, Stockler S, Elliott AM, Dragojlovic N, Lynd LD, Weymann D. Real-world outcomes of genome-wide sequencing for developmental and seizure disorders: Evidence from Canada. Genetics in Medicine. 2024; 26(4):1–12.
  4. Weymann D, Krebs E, Regier DA. Addressing immortal time bias in precision medicine: Practical guidance and methods development. Health Services Research. 2025; 60(1):1–11.

2023

  1. Pataky R, Peacock S, Bryan S, Sadatsafavi M, Regier DA. Real-world cost-effectiveness of a policy of KRAS testing to inform cetuximab or panitumumab for third-line therapy of metastatic colorectal cancer in British Columbia, Canada. Pharmacoeconomics Open. 2023; 7(6):997–1006.
  2. Weymann D, Chan B, Regier DA. Genetic matching for time-dependent treatments: A longitudinal extension and simulation study. BMC Medical Research Methodology. 2023; 23(1):1–13.

2021

  1. Weymann D, Laskin J, Jones SJM, Lim H, Renouf DJ, Roscoe R, Schrader KA, Sun S, Yip S, Marra MA, Regier DA. Matching methods in precision oncology: An introduction and illustrative example. Molecular Genetics and Genomic Medicine. 2021; 9(1):e1554.
  2. Weymann D, Pollard S, Chan B, Titmuss E, Bohm A, Laskin J, Jones SJM, Pleasance E, Nelson J, Fok A, Lim H, Renouf DJ, Schrader KA, Sun S, Yip S, Schaeffer DF, Marra MM, Regier DA. Clinical and cost outcomes following genomics-informed treatment for advanced cancers. Cancer Medicine. 2021; 10(15):5131–5140.